Compare Medtronic PLC (MDT) vs TeraWulf Inc (WULF) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

WULF trades at $18.86, up 3.85% today, but remains in a bearish technical trend. The company reported a net loss of -$661.42M in 2025 with a -611.46% net margin, though it secured a significant 20-year, $19B AI infrastructure deal with Anthropic. Analyst consensus is unanimously bullish with a $37.22 price target, citing long-term AI data center growth potential despite near-term profitability challenges.

The outlook hinges on successful execution of the Anthropic partnership to drive future revenue, but high valuation multiples and persistent losses pose substantial risks. Investors face volatility from operational cash burn and sector sentiment swings, requiring careful risk assessment against transformative AI infrastructure opportunities.